Alan H. Auerbach - 18 Feb 2026 Form 4 Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Reporting relationship: President and CEO, Director, 10%+ Owner
Issuer ticker: PBYI
Reported as of: 18 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Feb 2026, 20:29:13 UTC
Prior SEC filing: 08 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Gordon Esplin as attorney-in-fact for Alan H. Auerbach

Key filing fact

Alan H. Auerbach filed Form 4 for PUMA BIOTECHNOLOGY, INC. (PBYI) on 20 Feb 2026.

Key facts

This page summarizes Alan H. Auerbach's Form 4 filing for PUMA BIOTECHNOLOGY, INC. (PBYI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Feb 2026, 20:29.

Change

Previous filing in this sequence was filed on 08 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001358285 Primary reporting owner

AUERBACH ALAN H

Relationship: President and CEO, Director, 10%+ Owner
Address: C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 1700, LOS ANGELES
Signature: /s/ Gordon Esplin as attorney-in-fact for Alan H. Auerbach
Signature date: 20 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PBYI transaction

Common Stock

Award

Transaction value: $0
Shares: +159,778
Change %: +2.2%
Price: $0.000000
Shares after: 7,305,729
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PBYI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +227,474
Change %
Price: $0.000000
Shares after: 227,474
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 227,474
Exercise price: $6.68
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the grant of Restricted Stock Units ('RSUs"). Subject to the Reporting Person's continued status as an Employee of the Company, the RSUs shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to acceleration in certain events.

Footnote F2

Subject to the Reporting Person's continued status as an Employee of the Company, the Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares of Common Stock subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to acceleration in certain events.